Total Payments
$4,279
2023 Payments
$389.29
Companies
10
Transactions
28
Medicare Patients
1,465
Medicare Billing
$136,684
Payment Breakdown by Category
Research$1,898 (44.3%)
Travel$1,105 (25.8%)
Food & Beverage$1,051 (24.6%)
Education$225.89 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,898 | 10 | 44.3% |
| Travel and Lodging | $1,105 | 3 | 25.8% |
| Food and Beverage | $1,051 | 8 | 24.6% |
| Education | $225.89 | 7 | 5.3% |
Payments by Type
General
$2,381
18 transactions
Research
$1,898
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Corcept Therapeutics | $1,818 | 9 | $0 (2019) |
| Novo Nordisk AS | $1,613 | 4 | $0 (2017) |
| Novo Nordisk Inc | $225.89 | 7 | $0 (2023) |
| Medtronic, Inc. | $141.66 | 1 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $122.97 | 1 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $114.97 | 1 | $0 (2018) |
| Theratechnologies Inc. | $80.00 | 1 | $0 (2018) |
| PFIZER INC. | $75.65 | 1 | $0 (2019) |
| Lilly USA, LLC | $65.80 | 2 | $0 (2019) |
| Abbott Laboratories | $21.74 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $389.29 | 9 | Novo Nordisk Inc ($225.89) |
| 2020 | $122.97 | 1 | SANOFI-AVENTIS U.S. LLC ($122.97) |
| 2019 | $1,959 | 12 | Corcept Therapeutics ($1,818) |
| 2018 | $194.97 | 2 | Ipsen Biopharmaceuticals, Inc ($114.97) |
| 2017 | $1,613 | 4 | Novo Nordisk AS ($1,613) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $141.66 | General |
| Category: Durable Pump | ||||||
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 11/17/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/18/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Diabetes Care | ||||||
| 03/10/2020 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $122.97 | General |
| Category: Endocrinology | ||||||
| 05/09/2019 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $54.83 | General |
| Category: Diabetes | ||||||
| 05/09/2019 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $10.97 | General |
| Category: Diabetes | ||||||
| 04/03/2019 | Corcept Therapeutics | — | — | In-kind items and services | $772.40 | Research |
| Study: Study 455 | ||||||
| 04/03/2019 | Corcept Therapeutics | — | — | In-kind items and services | $206.80 | Research |
| Study: Study 455 | ||||||
| 04/03/2019 | Corcept Therapeutics | — | — | In-kind items and services | $153.57 | Research |
| Study: Study 455 | ||||||
| 04/03/2019 | Corcept Therapeutics | — | — | In-kind items and services | $92.86 | Research |
| Study: Study 455 | ||||||
| 03/22/2019 | PFIZER INC. | SOMAVERT (Drug) | Food and Beverage | In-kind items and services | $75.65 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 03/07/2019 | Corcept Therapeutics | — | — | In-kind items and services | $19.66 | Research |
| Study: Study 455 | ||||||
| 03/06/2019 | Corcept Therapeutics | — | — | Cash or cash equivalent | $52.07 | Research |
| Study: Study 455 | ||||||
| 03/06/2019 | Corcept Therapeutics | — | — | Cash or cash equivalent | $51.77 | Research |
| Study: Study 455 | ||||||
| 03/06/2019 | Corcept Therapeutics | — | — | Cash or cash equivalent | $18.00 | Research |
| Study: Study 455 | ||||||
| 01/24/2019 | Corcept Therapeutics | — | — | In-kind items and services | $450.60 | Research |
| Study: Study 455 | ||||||
| 10/18/2018 | Ipsen Biopharmaceuticals, Inc | Somatuline Depot (Drug) | Food and Beverage | In-kind items and services | $114.97 | General |
| Category: Oncology/Endocrinology | ||||||
| 02/08/2018 | Theratechnologies Inc. | EGRIFTA (Drug) | — | Cash or cash equivalent | $80.00 | Research |
| Study: EMR 200147-500 EGRIFTA • Category: HIV | ||||||
| 08/16/2017 | Novo Nordisk AS | FIASP (Drug) | Travel and Lodging | In-kind items and services | $514.22 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study 455 | Corcept Therapeutics | $1,818 | 9 |
| EMR 200147-500 EGRIFTA | Theratechnologies Inc. | $80.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 353 | 587 | $166,997 | $34,842 |
| 2022 | 7 | 352 | 608 | $158,116 | $35,496 |
| 2021 | 7 | 340 | 527 | $101,194 | $34,703 |
| 2020 | 10 | 420 | 539 | $101,894 | $31,643 |
Total Patients
1,465
Total Services
2,261
Medicare Billing
$136,684
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 162 | 286 | $107,471 | $22,441 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 33 | $16,910 | $3,797 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 58 | $15,226 | $3,594 | 23.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 32 | 72 | $10,109 | $1,590 | 15.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 25 | $6,392 | $1,525 | 23.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 26 | $3,744 | $918.48 | 24.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 51 | 75 | $6,365 | $632.37 | 9.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $780.00 | $344.16 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 155 | 285 | $102,348 | $24,075 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 58 | $14,420 | $3,529 | 24.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 43 | $10,433 | $2,340 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 14 | $6,714 | $1,686 | 25.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 27 | 64 | $8,586 | $1,555 | 18.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 15 | $5,160 | $1,176 | 22.8% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 75 | 129 | $10,455 | $1,135 | 10.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 173 | 297 | $69,194 | $26,523 | 38.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 25 | $8,813 | $2,728 | 30.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 29 | $4,751 | $1,741 | 36.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 23 | $3,797 | $1,240 | 32.7% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 76 | 118 | $8,881 | $1,053 | 11.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 14 | 14 | $3,136 | $845.24 | 27.0% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 14 | 21 | $2,622 | $573.30 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 158 | 216 | $48,600 | $16,187 | 33.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 51 | 52 | $17,836 | $4,412 | 24.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 49 | 55 | $8,449 | $2,722 | 32.2% |
About Dr. Jonea Lim, MD
Dr. Jonea Lim, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285774331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonea Lim, MD has received a total of $4,279 in payments from pharmaceutical and medical device companies, with $389.29 received in 2023. These payments were reported across 28 transactions from 10 companies. The most common payment nature is "" ($1,898).
As a Medicare-enrolled provider, Lim has provided services to 1,465 Medicare beneficiaries, totaling 2,261 services with total Medicare billing of $136,684. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Internal Medicine
- Location Oklahoma City, OK
- Active Since 02/07/2007
- Last Updated 05/09/2017
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1285774331
Products in Payments
- FIASP (Drug) $1,613
- MINIMED 780G (Device) $141.66
- SOLIQUA 100/33 (Biological) $122.97
- Somatuline Depot (Drug) $114.97
- EGRIFTA (Drug) $80.00
- SOMAVERT (Drug) $75.65
- TRULICITY (Drug) $65.80
- FREESTYLE LIBRE 3 (Device) $21.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Oklahoma City
Cheryl Black, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $71,246
Endocrinology, Diabetes & Metabolism $71,246
Christian Mangrum, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $37,310
Endocrinology, Diabetes & Metabolism $37,310
Dr. Diana Kennedy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $13,927
Endocrinology, Diabetes & Metabolism $13,927
R Scofield, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $12,515
Endocrinology, Diabetes & Metabolism $12,515
Dr. Niyaz Gosmanov, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $8,950
Endocrinology, Diabetes & Metabolism $8,950
Dr. Bassam Arodak, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $8,489
Endocrinology, Diabetes & Metabolism $8,489